D'Ettorre G - Search Results

1

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).

Mussini C, Roncaglia E, Borghi V, Rusconi S, Nozza S, Cattelan AM, Segala D, Bonfanti P, Di Biagio A, Barchi E, Focà E, Degli Antoni A, Bonora S, Francisci D, Limonta S, Antinori A, D'Ettorre G, Maggiolo F. Mussini C, et al. PLoS One. 2019 Sep 27;14(9):e0222650. doi: 10.1371/journal.pone.0222650. eCollection 2019. PLoS One. 2019. PMID: 31560700 Free PMC article. Clinical Trial.

2

Circulating levels of interleukin-7 in antiretroviral-naïve and highly active antiretroviral therapy-treated HIV-infected patients.

Mastroianni CM, Forcina G, d'Ettorre G, Lichtner M, Mengoni F, D'Agostino C, Vullo V. Mastroianni CM, et al. HIV Clin Trials. 2001 Mar-Apr;2(2):108-12. doi: 10.1310/6V29-4UU5-Y3FP-JERT. HIV Clin Trials. 2001. PMID: 11590518 Clinical Trial.

3

Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.

d'Ettorre G, Zaffiri L, Ceccarelli G, Andreotti M, Massetti AP, Vella S, Mastroianni CM, Vullo V. d'Ettorre G, et al. HIV Clin Trials. 2007 May-Jun;8(3):182-8. doi: 10.1310/hct0803-182. HIV Clin Trials. 2007. PMID: 17621465 Clinical Trial.

4

Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.

Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Bonora S, et al. J Med Virol. 2009 Mar;81(3):400-5. doi: 10.1002/jmv.21405. J Med Virol. 2009. PMID: 19152404

5

Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.

Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M; ISS-NIA Group. Baroncelli S, et al. Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6. Ann Pharmacother. 2010. PMID: 20371753 Clinical Trial.

6

Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.

Fabbiani M, Di Giambenedetto S, Ragazzoni E, D'Ettorre G, Parruti G, Prosperi M, Bracciale L, Cauda R, Navarra P, De Luca A. Fabbiani M, et al. Pharmacol Res. 2011 Mar;63(3):249-53. doi: 10.1016/j.phrs.2010.11.009. Epub 2010 Dec 2. Pharmacol Res. 2011. PMID: 21130167

7

Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy.

d'Ettorre G, Forcina G, Ceccarelli G, Andreotti M, Andreoni C, Rizza C, Massetti AP, Sarmati L, Mastroianni CM, Vella S, Andreoni M, Vullo V. d'Ettorre G, et al. J Chemother. 2011 Feb;23(1):24-7. doi: 10.1179/joc.2011.23.1.24. J Chemother. 2011. PMID: 21482490

8

Induced first abortion rates before and after HIV diagnosis: results of an Italian self-administered questionnaire survey carried out in 585 women living with HIV.

Ammassari A, Cicconi P, Ladisa N, Di Sora F, Bini T, Trotta MP, D'Ettorre G, Cattelan AM, Vichi F, d'Arminio Monforte A; DiDi Study Group. Ammassari A, et al. HIV Med. 2013 Jan;14(1):31-9. doi: 10.1111/j.1468-1293.2012.01032.x. Epub 2012 Jun 26. HIV Med. 2013. PMID: 22731856 Free article.

9

Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.

Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D, Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni O, Verucchi G, Floridia M; ISS-NIA study group. Bucciardini R, et al. Int J STD AIDS. 2012 Jul;23(7):459-63. doi: 10.1258/ijsa.2012.011391. Int J STD AIDS. 2012. PMID: 22843997 Clinical Trial.

10

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.

Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, Bucciardini R; ISS-NIA Study Group. Weimer LE, et al. J Antimicrob Chemother. 2013 Jan;68(1):193-9. doi: 10.1093/jac/dks341. Epub 2012 Sep 14. J Antimicrob Chemother. 2013. PMID: 22984206 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

346 results

Search Page